• Meet us at ISPOR US 2025 in Montreal Quebec, May 13-16. Connect with us via the ISPOR app.
Coreva Scientific Coreva Scientific Coreva Scientific Coreva Scientific
  • Home
  • Solutions
  • Experience
  • Partners
  • Publications
  • About Us
Coreva Scientific Coreva Scientific
  • Home
  • Solutions
  • Experience
  • Partners
  • Publications
  • About Us
Coreva Scientific / Market access / From first concepts to market: Developing value
Aug 15

From first concepts to market: Developing value

  • August 15, 2018
  • Market access

Reimbursement is one gateway to medical device sales. It is not always attainable, and devices often fall under procedure codes. This makes it imperative to have a rounded sales strategy that has a value narrative from concept to long-term value. Here are some key items to keep in mind when building the three pillars of medical device value for your own product.

Clinical value

Efficacy and safety endpoints must be clearly defined and agreed upon by both company and physician stakeholders. Being the best product for a redundant endpoint is of no value. One study may be persuasive, more are better and open the door to meta-analyses and reviews.

Health-economic value

Cost concerns over a product can negate any medical benefit. Health economics combines clinical and cost data to quantify the financial impact of change in healthcare practice. Plan to collect cost and quality-of-life data alongside your clinical studies.

Real-world evidence

Data should also be collected outside of a randomized, controlled trial (RCT). There are concerns that an RCT does not reflect standard practice, making the results non-generalizable. A major oversight is when companies fail to plan for these real-world health outcomes studies.

Burden of disease

Valuable data are of little impact without context. Does your customer understand the unmet needs and cost of treating a particular condition? These details can be crucial to your value messaging hitting its mark.

Value-based healthcare

With cost being a major concern, providers are reluctant to change the status quo and trial a new product. To counter this obstacle, well-designed risk sharing agreements can be implemented, whereby the company is paid only for benefits provided. Options for risk sharing should be considered early, as they can open the door to extensive market penetration.

Categories

Recent Posts

  • New whitepaper: The role of single-patient ECG in reducing infection
  • New publication on the impact of out-of-hospital cervical ripening
  • HTAi 2021 Annual Meeting: INNOVATION THROUGH HTA
  • New publication on the impact of capnography monitoring
  • E-learning: Can my hospital benefit from next-generation sequencing?

Coreva Scientific provides consultancy services to companies with an interest in healthcare.


Sitemap

  • Home
  • Solutions
  • Experience
  • Partners
  • Publications
  • About Us
  • Contact
  • Career

Solutions

  • Evidence communication
  • Detailed evidence
  • Strategic consulting
  • Data identification
  • Data-analysis
  • Data generation and expert opinion
  • Economic models
© 2022 Coreva Scientific GmbH & Co KG
  • Imprint
  • Data privacy statement
  • Cookies
  •  

  •  

  •  

  •